MannKind Corp Files 10-Q for Period Ending March 31, 2024

TL;DR

<b>MannKind Corp filed its Q1 2024 10-Q, detailing financial instruments and agreements with entities like United Therapeutics.</b>

AI Summary

MANNKIND CORP (MNKD) filed a Quarterly Report (10-Q) with the SEC on May 8, 2024. MannKind Corporation filed a 10-Q report for the period ending March 31, 2024. The filing includes data related to various financial instruments and agreements, such as Senior Notes, MidCap Credit Facility, and Convertible Promissory Notes. Specific entities mentioned in relation to agreements include United Therapeutics Corporation and Biomm SA. The report details financial elements like Milestone Rights Liability, Accrued Liabilities, and Operating Lease Liability. Key dates and periods referenced include Q1 2024, Q1 2023, and fiscal year-end 2023.

Why It Matters

For investors and stakeholders tracking MANNKIND CORP, this filing contains several important signals. This filing provides a snapshot of MannKind's financial health and contractual obligations as of Q1 2024, crucial for investors assessing the company's stability and future prospects. The mention of specific agreements and liabilities offers insight into MannKind's ongoing business operations and potential revenue streams or financial commitments.

Risk Assessment

Risk Level: medium — MANNKIND CORP shows moderate risk based on this filing. The filing contains numerous financial instruments and agreements, requiring detailed analysis to fully understand the company's financial position and associated risks.

Analyst Insight

Investors should review the detailed breakdown of financial liabilities and agreements to assess the company's financial risk and operational strategy.

Revenue Breakdown

Key Numbers

• 2024-03-31 — Reporting Period End Date (10-Q filing)
• 2023-12-31 — Prior Period End Date (10-Q filing)
• 2024-05-08 — Filing Date (10-Q filing)

Key Players & Entities

• MANNKIND CORP (company) — Filer name
• United Therapeutics Corporation (company) — Party to collaboration and license agreement
• Biomm SA (company) — Party to supply and distribution agreement
• The Mann Group LLC (company) — Related party for convertible promissory note
• Zealand Pharma US (company) — Mentioned in context of 2023-03-31
• 2024-03-31 (date) — Reporting period end date
• 2023-12-31 (date) — Prior period end date
• 2024-05-08 (date) — Filing date

FAQ

Risk Factors

• Milestone Rights Liability [medium — financial]: The company has a Milestone Rights Liability, with fair value disclosures based on Level 3 inputs, indicating potential future financial obligations.
• Senior Notes [medium — financial]: The company has Senior Notes outstanding, with details on carrying amounts and fair value disclosures, representing significant debt.
• MidCap Credit Facility [medium — financial]: MannKind has a MidCap Credit Facility with specific tranches and minimum/maximum amounts, indicating borrowing capacity and obligations.

Key Financial Figures

• $0.01 — ch registered Common Stock, par value $0.01 per share MNKD The Nasdaq Stock Mar

Filing Documents

• mnkd-20240331.htm (10-Q) — 2375KB
• mnkd-ex31_1.htm (EX-31.1) — 13KB
• mnkd-ex31_2.htm (EX-31.2) — 13KB
• mnkd-ex32_1.htm (EX-32.1) — 9KB
• mnkd-ex32_2.htm (EX-32.2) — 9KB
• 0000950170-24-055661.txt (&nbsp;) — 12730KB
• mnkd-20240331.xsd (EX-101.SCH) — 2274KB
• mnkd-20240331_htm.xml (XML) — 2243KB

: FINANCIAL INFORMATION

PART I: FINANCIAL INFORMATION 2

Financial Statements (Unaudited)

Item 1. Financial Statements (Unaudited) 2 Condensed Consolidated Statements of Operations: Three months ended March 31, 2024 and 2023 2 Condensed Consolidated Balance Sheets: March 31, 2024 and December 31, 2023 3 Condensed Consolidated Statements of Stockholders' Deficit: Three months ended March 31, 2024 and 2023 4 Condensed Consolidated Statements of Cash Flows: Three months ended March 31, 2024 and 2023 5 Notes to Condensed Consolidated Financial Statements 6

Management's Discussion and Analysis of Financial Condition and Results of Operations

Item 2. Management's Discussion and Analysis of Financial Condition and Results of Operations 33

Quantitative and Qualitative Disclosures About Market Risk

Item 3. Quantitative and Qualitative Disclosures About Market Risk 39

Controls and Procedures

Item 4. Controls and Procedures 39

: OTHER INFORMATION

PART II: OTHER INFORMATION 40

Legal Proceedings

Item 1. Legal Proceedings 40

Risk Factors

Item 1A. Risk Factors 40

Unregistered Sales of Equity Securities and Use of Proceeds

Item 2. Unregistered Sales of Equity Securities and Use of Proceeds 69

Defaults Upon Senior Securities

Item 3. Defaults Upon Senior Securities 69

Mine Safety Disclosures

Item 4. Mine Safety Disclosures 69

Other Information

Item 5. Other Information 69

Exhibits

Item 6. Exhibits 70

SIGNATURES

SIGNATURES 71 1 PART 1: FINANCIA L INFORMATION

FINANCI AL STATEMENTS

ITEM 1. FINANCI AL STATEMENTS MANNKIND CORPORATION AND SUBSIDIARIES CONDENSED CONSOLIDAT ED STATEMENTS OF OPERATIONS (Unaudited) Three Months Ended March 31, 2024 2023 (In thousands except per share data) Revenues: Net revenue – commercial product sales $ 18,764 $ 17,562 Revenue – collaborations and services 24,848 11,386 Royalties – collaborations 22,651 11,678 Total revenues 66,263 40,626 Expenses: Cost of goods sold 3,819 5,530 Cost of revenue – collaborations and services 14,779 10,683 Research and development 10,013 5,605 Selling 11,601 13,310 General and administrative 10,728 10,542 (Gain) loss on foreign currency transaction ( 1,399 ) 954 Total expenses 49,541 46,624 Income (loss) from operations 16,722 ( 5,998 ) Other income (expense): Interest income, net 3,434 1,302 Interest expense on financing liability ( 2,447 ) ( 2,424 ) Interest expense ( 2,567 ) ( 2,786 ) Interest expense on liability for sale of future royalties ( 4,248 ) — Other income — 111 Total other expense ( 5,828 ) ( 3,797 ) Income (loss) before income tax expense 10,894 ( 9,795 ) Income tax expense 264 — Net income (loss) $ 10,630 $ ( 9,795 ) Net income (loss) per share – basic $ 0.04 $ ( 0.04 ) Weighted average shares used to compute net income (loss) per share – basic 270,356 263,969 Net income (loss) per share – diluted $ 0.04 $ ( 0.04 ) Weighted average shares used to compute net income (loss) per share – diluted 324,733 263,969 See notes to condensed consolidated financial statements. 2 MANNKIND CORPORATION AND SUBSIDIARIES CONDENSED CONSOLIDA TED BALANCE SHEETS (Unaudited) March 31, 2024 December 31, 2023 (In thousands except share and per share data) ASSETS Current assets: Cash and cash equivalents $ 193,272 $ 238,480 Short-term investments

View Full Filing

View this 10-Q filing on SEC EDGAR